TEZSPIRE is indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma. TEZSPIRE is not indicated for the relief of acute bronchospasm or status asthmaticus. Come see what's UP at the TEZSPIRE Booth The next era of severe asthma management has emerged Rise above the complexity The FIRST & ONLY biologic approved for severe asthma without phenotypic or biomarker limitations1 Aim higher. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS Known hypersensitivity to tezepelumab-ekko or excipients. WARNINGS AND PRECAUTIONS Hypersensitivity Reactions Hypersensitivity reactions (eg, rash and allergic conjunctivitis) can occur following administration of TEZSPIRE. These reactions can occur within hours of administration, but in some instances have a delayed onset (ie, days). In the event of a hypersensitivity reaction, initiate appropriate treatment as clinically indicated and then consider the benefits and risks for the individual patient to determine whether to continue or discontinue treatment with TEZSPIRE. Please see additional Important Safety Information on back and accompanying full Prescribing Information, including Patient Information.https://www.tezspirehcp.com/